Благодарности. Выражаю глубокую благодарность моему научному руководителю Есипову Роману Станиславовичу за предоставленную мне тему

Выражаю глубокую благодарность моему научному руководителю Есипову Роману Станиславовичу за предоставленную мне тему, помощь при выполнении и написании работы, поддержку и внимание.

Особую благодарность выражаю Степаненко Василию Николаевичу, Чуповой Ларисе Анатольевне и Ярославцевой Анастасии Константиновне за неоценимую помощь в подготовке и проведении экспериментов, плодотворном обсуждении результатов и помощь в написании работы.

Список литературы

1. Базин И., Гарин А. Таргентные антиангиогенные препараты в терапии солидных опухолей. Врач 2008, 11: 52-55.

2. Кузьмин А.Г., Липатов Д.В., Смирнова О.М., Шестакова М.В. Анти-VEGF препараты для лечения диабетической ретинопатии. Офтальмохирургия. 2009, 3: 15-19.

3. Парфенова Е.В., Ткачук В.А. Перспективы генной терапии сердечно-сосудистых заболеваний. Вопр. мед. хим. 2000, 46: 293–310.

4. Arora N., Masood R., Zheng T., J. Cai, D.L. Smith, P.S. Gill. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res. 1999, 59: 183–188.

5. Baneyx F., Recombinant protein expression in Escherichia coli, Curr. Opin. Biotechnol. 1999, 10: 411–421

6. Barleon B, Sozzani S, Zhou D, Weich H A, Mantovani A, Marme D. Migration of human monocytesin response vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996, 87: 3336–3343.

7. Bonnie J. Nieves, Patricia A. D’Amore, and Brad A. Bryan. The function of vascular endothelial growth factor International Union of Biochemistry and Molecular Biology, Inc.Volume 2007 35, 332–337

8. Cantell, K. The Story of Interferon, 1998.

9. Cao R, Brakenhielm E, Pawliuk R. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF. NatMed. 2003, 9: 604–13.

10. Casella I, Feccia T, Chelucci C, Samoggia P, Castelli G, Guerriero R, Parolini I, Petrucci E, Pelosi E, Morsilli O, Gabbianelli M, Testa U, Peschle C. Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor. Blood. 2003, 101(4):1316–23.

11. Christensen J. G. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Annals of oncology. 2007, 18 1375-1381.

12. Clauss M, Weich H, Breier G, Knies U, Rockl W, Waltenberger J, Risau W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J BiolChem. 1996; 271(30): 17629–17634.

13. Compernolle V, Brusselmans K, Acker T, Hoet P, Tjwa M, Beck H, Plaisance S, Dor Y, Keshet E, Lupu F, Nemery B, Dewerchin M, Van Veldhoven P, Plate K, Moons L, Collen D, Carmeliet P. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med. 2002, 8(7): 702–10.

14. Dikov MM, Ohm JE, Ray N, Tchekneva EE, Burlison J, Moghanaki D, Nadaf S. Carbone DP. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol. 2005, 174(1): 215–22.

15. Duyndam MC, Hilhorst MC, Schluper HM, Verheul HM, van Diest PJ, Kraal G, Pinedo HM, Boven E. Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. Am J Pathol. 2002, 160 (2): 537–48.

16. Ellen C. Breen. VEGF in Biological Control. Journal of Cellular. Biochemistry. 2007, 102: 1358–1367.

17. Farahani M, Treweeke AT, Toh CH, Till KJ, Harris RJ, Cawley JC, Zuzel M, Chen H. Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia. 2005, 19(4): 524–30.

18. Ferrara N. Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action, Mol. Biol. Cell. 2010, 21: 687–690.

19. Feistritzer C, Kaneider NC, Sturn DH, Mosheimer BA, Kahler CM, Wiedermann CJ. Expression and function of the vascular endothelial growth factor receptor FLT-1 in human eosinophils. Am JRespir Cell MolBiol. 2004, 30(5): 729–35.

20. Graumann K., Premstaller A. Manufacturing of recombinant therapeutic proteins in microbial systems. Biotechnol. J. 2006, 1: 164–186.

21. Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G, Hong K, Marsters JC, Ferrara N. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature. 2002, 417(6892): 954–958.

22. Geum Young Lee, Woon Won Jung, Chang Soo Kang, In Seok Bang. Expression and characterization of human vascular endothelial growth factor (VEGF 165) in insect cells Protein Expression and Purification. 2006, 46: 503–509.

23. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Yung S, Chimenti S, Landsman L, Abramovitch R, Keshet E. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell. 2006, 124(1): 175–189.

24. Hyo Jin Ihm, Seung-Ju Yang, Jae-Wan Huh, Soo Young Choi Sung-Woo Cho. Soluble expression and purification of synthetic human bone morphogenetic protein-2 in Escherichia coli, BMP Rep. 2008, 31;41(5): 404-7.

25. I-Liang Lee, Pei-Shan Li, Wei-Lin Yu, Hsin-Hsin Shen. Prokaryotic expression, refolding, and purification of functional human vascular endothelial growth factor isoform 165: Purification procedures and refolding conditions revisited. Protein Expression and Purification. 2011, 76: 54–58.

26. Ishida S., Usui T., Yamashiro K. VEGF165 as the pathophisiological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol. Vis. Sci. 2004, 45: 368-374.

27. Iwaguro H, Yamaguchi J, Kalka C, Murasawa S, Masuda H, Hayashi S, Silver M, Li T, Isner JM, Asahara T. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation. 2002, 105(6): 732–8.

28. Keck, P. J., Hauser, S. D., Krivi, G., Sanzo, K., Warren, T., Feder, J., and Connolly, D. T. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989, 246: 1309–1312.

29. Keck R.G., Berleau L., Harris R., Keyt B.A. Disulfide structure of the heparin binding domain in vascular endothelial growth factor: characterization of posttranslational modifications in VEGF. Arch. Biochem. Biophys. 1997, 344: 103–113

30. Kim S., Mohamedali K.A., Cheung L.H., Rosenblum M.G. Overexpression of biologically active VEG121 fusion proteins in Escherichia coli, J. Biotechnol. 2007, 128: 638–647

31. Lee Seong-Baek, Jeong Soo Park, Seunghee Lee, Junho Park. Overproduction of Recombinant Human VEGF in Chinese Hamster Ovary Cell, J. Microbiol. Biotechnol. 2008, 18 (1): 183-187.

32. Lissandra Dal Lago, Veronique D’hondt, Ahmad Awada. Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors. The Oncologist. 2008, 13: 845-858.

33. Matsumoto Taro, Mugishima Hideo. Signal transduction via vascular endothelial growth factor (VEGF) receptors and their roles in atherogenesis. J. of atherosclerosis and thrombosis. 2006, 13 (3): 130-135.

34. Miquerol, L., Langille, B. L., and Nagy, A. Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development. 2000, 127: 3941–3946.

35. Morera Y., Lamdan H., Bequet M., Ayala M., Rojas G., Muñoz Y.,. Gavilondo J.V. Biologically active vascular endothelial growth factor as a bacterial recombinant glutathione S-transferase fusion protein, Biotechnol. Appl. Biochem. 2006, 44: 45–53.

36. Muller YA, Christinger HW, Keyt BA, de Vos AM. The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding. Structure. 1997, 15;5(10): 1325-38

37. Murayama T, Tepper OM, Silver M, Ma H, Losordo DW, Isner JM, Asahara T, Kalka C. Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization in vivo. Exp Hematol. 2002, 30(8): 967–72.

38. Norrby K. Mast cells and angiogenesis. Apmis. 2002, 110 (5): 355–71.

39. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, Van Dorpe J, Hellings P, Gorselink M, Heymans S, Theilmeier G, Dewerchin M, Laudenbach V, Vermylen P, Raat H, Acker T, Vleminckx V, Van Den Bosch L, Cashman N, Fujisawa H, Drost MR, Sciot R, Bruyninckx F, Hicklin DJ, Ince C, Gressens P, Lupu F, Plate KH, Robberecht W, Herbert JM, Collen D, Carmeliet P. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet. 2001, 28(2): 131–8.

40. Otrock, Z. K., Makarem, J. A., and Shamseddine, A. I. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol. Dis. 2007, 38: 258–268.

41. Peretz D., Gitay-Goren H., Safran M., Kimmel N., Gospodarowicz D., Neufeld G. Glycosylation of vascular endothelial growth factor is not required for its mitogenic activity, Biochem. Biophys. Res. Commun. 1992, 182: 1340–1347.

42. Rissanen TT, Yla-Herttuala S. Current status of cardiovascular gene therapy. MolTher. 2007, 15: 1233–47.

43. Robert J. Motzer, M. Dror Michaelson, Bruce G. Redman, Gary R. Hudes, George Wilding, Robert A. Figlin, Michelle S. Ginsberg, Sindy T. Kim, Charles M. Baum, Samuel E. DePrimo, Jim Z. Li, Carlo L. Bello, Charles P. Theuer, Daniel J. George, and Brian I. Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma. The Journal of Clinical Oncology. 2006, 24 (1): 16-24.

44. Rosana D. Meyer, David B. Sacks, and Nader Rahimi. IQGAP1-Dependent Signaling Pathway Regulates Endothelial Cell Proliferation and Angiogenesis. PLoS ONE. 2008, 3(12): e3848.

45. Scrofani S.D.B., Fabri L.J., Xu P., P. Maccarone, A.D. Nash. Purification and refolding of vascular endothelial growth factor-B, Protein Sci. 2000, 9: 2018–2025.

46. Salvatore Grisatni, Fock Ziemssen. Bevacizumab: Off-label use on ophthalmology. Indian J Opthtalmol. 2007, 55 (6): 417-420.

47. Schanzer A, Wachs FP, Wilhelm D, Acker T, Cooper-Kuhn C, Beck H, Winkler J, Aigner L, Plate KH, Kuhn HG. Direct stimulation of adult neural stem cells in vitro and neurogenesis in vivo by vascular endothelial growth factor. Brain Pathol. 2004, 14(3): 237–248.

48. Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., and Dvorak, H. F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983, 219: 983–985.

49. Shalini Iyer and K. Ravi Acharya. Tying the knot. The cystine signature and molecular-recognition processes of the vascular endothelial growth factor family of angiogenic cytokines. FEBS Journal. 2011, 278: 4304–4322.

50. Shelly A. Pizarro, Jane Gunson, Matthew J. Field, Rachel Dinges, Stefanie Khoo, Milind Dalal, Michael Lee, Kimberly A. Kaleas, Kathryn Moiseff, Susan Garnick, Dorothea E. Reilly, Michael W. Laird, Charles H. Schmelzer. High-yield expression of human vascular endothelial growth factor VEGF 165 in Escherichia coli and purification for therapeutic applications. Protein Expression and Purification. 2010, 72: 184–193.

51. Shui YB, Wang X, Hu JS, Wang SP, Garcia CM, Potts JD, Sharma Y, Beebe DC. Vascular endothelial growth factor expression and signaling in the lens. Invest Ophthal mol VisSci. 2003, 44 (9): 3911–3919.

52. ShyuK-G, ChangH, IsnerJM. Synergistic effect of angiopoietin-1 and vascular endothelial growth factor on neoangiogenesis in hypercholesterolemic rabbit model with acute hind limb ischemia. Life Sciences. 2003, 73: 563–79.

53. Street John and Lenehan Brian. Vascular endothelial growth factor regulates osteoblast survival –evidence for an autocrine feedback mechanism, J. of Orthopaedic Surgery and Research. 2009, 4: 19.

54. Swartz J.R. Advances in Escherichia coli production of therapeutic proteins. Curr. Opin. Biotechnol. 2001, 12: 195–201.

55. Wiesmann C., Fuh G., Christinger H.W., Eigenbrot C., Wells J.A., de Vos A.M. Crystal structure at 1.7 Å resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell. 1997, 91: 695–704.

56. Whitlock PR, Hackett NR, Leopold P Letal. Adenovirus-mediated transfer of a minigene expressing multiple isoforms of VEGF is more effective at inducing angiogenesis than comparable vectors expressing individual VEGF cDNAs. MolTher. 2004, 9: 67–75.

57. Yla-Herttuala S, Rissanen TT, Vajanto I. Vascular endothelial growth factors: biology and current status of clinical application in cardiovascular medicine. JMCC. 2007, 49: 1015–26.

Поиск по сайту: